ClinicalTrials.gg
CompletedNCT05944913TPN-RADUpdated Nov 13, 2026

Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy

An interventional study of Prevena in Soft Tissue Sarcoma, sponsored by Centre Leon Berard. Completed at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Centre Leon Berard · Not applicable, Interventional, and Other

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Sarcoma by Centre Leon Berard — 4 open to participants now, 8 under way, 1 of them phase 3. Sarcoma · Centre Leon Berard.

Enrollment
5th of 12
173 · median 99
Started
2023
with 1 other
No phase
6 of 16
2 open now
Registered
14th of 16
by date

Among the 16 studies in Sarcoma by Centre Leon Berard, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 6 with no phase, and was the 14th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

4 of the 16 studies in Sarcoma by Centre Leon Berard are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Sarcoma by Centre Leon Berard, or all of them as a file.
02

Study summary

This is a randomized (1:1 ratio), prospective, comparative, controlled, open-label study. The aim is to compare the efficacy of negative pressure therapy (PREVENA™) versus standard postoperative wound management on the wound healing after surgery for previously irradiated Soft Tissue Sarcoma (STS)

Read the detailed description

The gold standard treatment for primary non-metastatic STS is complete surgical resection. Peri-operative Radiation Therapy (RT) has been proved to improve local control . Nevertheless, the timing of RT, whether preoperative or postoperative, remains a debate.

Both have similar local control efficacy, but preoperative RT results in lower rates of long-term fibrosis and lymphedema and improved joint mobility than postoperative RT. On the other hand, the adverse effect of pre-operative RT is a higher rate of wound post-operative complications and re-operations.

Any effort to reduce the high rate of postoperative complications could offer the advantage of preoperative RT in terms of reduced long-term sequelae compared with postoperative RT without a higher wound complication rate postoperatively. Short retrospective series of Negative Pressure Wound Therapy (NPWT) after surgical resection of Soft Tissue Sarcoma (STS) have reported very encouraging results in preventing wound complications: patients treated with NPWT were less likely to develop wound complications than those who did not receive it. Both groups did not report an increased rate of local recurrence. The use of NPWT would also reduce the cost of care by avoiding complications.

That's why the investigators propose this study comparing the use of a negative pressure dressing to a conventional dressing in patients with STS of the limbs or trunk resected after neo-adjuvant external radiotherapy.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

Keywords

  • STS
  • Negative Pressure Wound Therapy
  • Surgery with preoperative irradiation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the day of consenting to the study
  • Patients with primary STS of the limb or trunk treated with preoperative external radiation therapy (decided in multidisciplinary board)
  • Intent to cure resection required for STS planned between 3 to 8 weeks after the end of RT
  • Planned primary wound closure, including local or distant jambeau
  • Ability to understand and willingness for follow-up visits
  • Covered by a medical insurance
  • Signed and dated document indicating that the patient has been informed of all aspects of the trial prior to enrolment.

Exclusion criteria

Exclusion Criteria:

  • Known hypersensibility to silver
  • Patients with a diagnosis of Ewing's sarcoma, chondrosarcoma, osteosarcoma, or desmoid tumor. Nota bene: Only patients with bone tumors are affected; patients with soft tissue tumors can be included in the study.
  • Patient in relapse setting;
  • Patient requiring a surgical revision after R1 or R2 resection;
  • Planned blade drainage;
  • Planned no wound-closure and skin graft after resection
  • Patient requiring authorship or curators or patient deprived of liberty.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    Arm A : Surgery for STS and prevena

    The surgery for the STS lesion will be performed according to standard practices. PREVENA™ Incision Management System should be applied immediately post-surgery to clean surgically closed wounds. It should be continuously applied for a minimum of 2 days and up to a maximum of 7 days (as per PREVENA user manual)

    Device: Prevena

  • No intervention
    Arm B : Surgery for STS and standard postoperative wound management

    The surgery for the STS lesion will be performed according to standard practices. The dressing and drainage of the wound will be performed according to usual practices, with the exception of negative pressure dressings.

Interventions

  • DevicePrevena

    PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.

06

What researchers measure

Primary outcomes

  1. The efficacy of negative pressure therapy (PREVENA) versus standard postoperative wound management on the wound healing after surgery for previously irradiated STS

    Assessed by major wound complications rate

    Time frame: Within the 3-month postoperative period.

Secondary outcomes

  1. Three month deep infection rate

    Assessed by the proportion of patients experiencing a second surgery for wound healing problem within 3 postoperative months

    Time frame: At 3 months post-surgery visit

  2. Three months secondary surgery for wound healing problem rate

    Assessed by the proportion of patients experiencing a second surgery for wound healing problem within 3 postoperative months

    Time frame: At 3 months post-surgery visit

  3. Hospitalization duration

    Defined as the number of hospitalization days from the date of surgery to the date of discharge

    Time frame: At 3 months post-surgery visit

  4. Time to complete wound healing

    Defined as the interval from surgery to 100% healing (total wound closure with no need for dressing and any local care)

    Time frame: Up to 27 months

  5. Number and types of major wound complications (MWCs)

    Assessed by a number and differens types of a major wound complications

    Time frame: Up to 27 months

  6. Quality of life using EQ-5D-5L

    Assessed by EQ-5D-5L introduce by EuroQol Group in 2009 with five dimensions : mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has five levels : no problems, slight problems, moderate problems, severe problems and extreme problems. A minimum value is 0 and a maximum value is 100. A mean worst value is 0 and a better mean value is 100.

    Time frame: At 28 days and 3 months after surgery for each patients

  7. Incidence of Adverse Events

    Defined by the number of patients with Adverse Events (any type and any grade using the NCI-CTC AE scale version 5.0)

    Time frame: Up to 27months

  8. Quality of life using FACT-G

    Assessed by FACT-G : Functionnal Assesment of Cancer Therapy with 27 items. There are four domains of HRQOL in cancer patients: Physical, social, emotional, and functional well-being. A minimum value is 0 and a maximum value is 4. A mean worst value is 0 and a better mean value is 108.

    Time frame: At 28 days and 3 months after surgery for each patients

07

Study locations

14 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Oct 2026, 38 months.

Of 145 non-industry interventional studies with no phase under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 120. This study's 38 months is below that.

Counting every sponsor, half of 148 studies reached it within 59 months; a quarter within 34 and three quarters within 120.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Aug 2026 → Oct 2026 and completion Nov 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Jul 13, 2023
StartActual
Aug 3, 2023
Primary completionActual
Oct 7, 2026was Aug 2026
CompletionActual
Oct 7, 2026was Nov 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Sites
1 site removed
Show 1 removed
  • Institut Curie · Paris, France
Nov 13, 2026
Primary completion
Aug 2026→Oct 7, 2026 (actual)
Nov 13, 2026
Study completion
Nov 2026→Oct 7, 2026 (actual)
Nov 13, 2026
Enrollment
166 (estimated)→173 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    1 site removed
    Show 1 removed
    • Institut Curie · Paris, France
    Primary completion Aug 2026→Oct 7, 2026 (now actual)
    Study completion Nov 2026→Oct 7, 2026 (now actual)
    Enrollment 166 (estimated)→173 (actual)
    + 3 other changes: verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05944913
Lead sponsor
Centre Leon Berard
Responsible party
Sponsor
First posted
Jul 13, 2023
Start date
Aug 3, 2023
Primary completion
Oct 7, 2026
Completion
Oct 7, 2026
Last update
Nov 13, 2026

Study contacts

François Gouin, MD, Chirurgien
principal investigator · Centre Leon Berard

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion